Tatiana S. Kain
HS Professor, Chief of Nuclear Medicine and Molecular Imaging, Radiological Sciences
School of Medicine
School of Medicine
MD: Ben-Gurion School of Medicine, Beer-Sheva, Israel (1987)
Residency: Mount Sinai Medical Center, New York, NY, Pathology (1989)
Residency: Yale-New Haven Hospital, New Haven, CT, Nuclear Medicine (1990)
Residency: Yale-New Haven Hospital, New Haven, CT, Diagnostic Radiology (1993)
Residency: Mount Sinai Medical Center, New York, NY, Pathology (1989)
Residency: Yale-New Haven Hospital, New Haven, CT, Nuclear Medicine (1990)
Residency: Yale-New Haven Hospital, New Haven, CT, Diagnostic Radiology (1993)
University of California, Irvine
101 The City Drive South, Rt. 140
Nuc Med, Bldg. 20
Mail Code: 5005
Orange, CA 92868
101 The City Drive South, Rt. 140
Nuc Med, Bldg. 20
Mail Code: 5005
Orange, CA 92868
Academic Distinctions
Orange County Medical Association “Physician of Excellence Award”, 2015-2019
American College of Radiology Fellow (FACR), 2016
American College of Radiology Fellow (FACR), 2016
Publications
Ou I, Hong S, Azada M, Hsiang D, David J, Herman J, Kain T, Siwak-Tapp C, Casey C, He J, Ali S, Klempner S, Miller V. Next-Generation Sequencing Reveals a Novel
NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High- Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib. Journal of Thoracic oncology 2014 April; 9(4): 549-53
“Early assessment of Axillary response with F-FDG PET/CT during neoadjuvant Chemotherapy in Stage II- III Breast Cancer: Implications for Surgical Management of the Axilla” Breast Diseases: A Year Book Quarterly Dec 5 2014
Bahri S, Kain TS, Mehtha RS, Herman J, Kuzucan A, Chen JH, Kolb HC, Walsh JC, Su MY. Initial Experience of Monitoring response of Breast Cancer to Bevacizumab containing Chemotherapy using A New Integrin Specific PET Imaging Tracer (F-18) RGD-K-5. Mol Imag Dynamic 2015, 5:116
Tang R, Kain T, Herman J, Seery T. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res. 2015; 7:357-60.
For full list of publications, please click on the link above.
NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High- Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib. Journal of Thoracic oncology 2014 April; 9(4): 549-53
“Early assessment of Axillary response with F-FDG PET/CT during neoadjuvant Chemotherapy in Stage II- III Breast Cancer: Implications for Surgical Management of the Axilla” Breast Diseases: A Year Book Quarterly Dec 5 2014
Bahri S, Kain TS, Mehtha RS, Herman J, Kuzucan A, Chen JH, Kolb HC, Walsh JC, Su MY. Initial Experience of Monitoring response of Breast Cancer to Bevacizumab containing Chemotherapy using A New Integrin Specific PET Imaging Tracer (F-18) RGD-K-5. Mol Imag Dynamic 2015, 5:116
Tang R, Kain T, Herman J, Seery T. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res. 2015; 7:357-60.
For full list of publications, please click on the link above.
Professional Societies
American College of Radiology
Radiological Society of North America
American College of Nuclear Medicine Physicians
Fellow, American College of Radiology (FACR)
Link to this profile
https://faculty.uci.edu/profile/?facultyId=5658
https://faculty.uci.edu/profile/?facultyId=5658
Last updated
04/22/2020
04/22/2020